Targeted Therapy Provides a Personalized Solution For Your Prostate Cancer Patients

CHOOSE THE MOST PERSONALIZED THERAPY FOR YOUR PATIENTS

Targeted therapy is an individual approach to treating prostate cancer which destroys localized disease identified by MRI and biopsy while sparing uninvolved tissue with the intention of reducing side effects and increasing quality of life.

ADVANTAGES
A targeted treatment may reduce patient anxiety of living with untreated cancer, while the use of Cs-131 can allow the patient to have further brachytherapy treatment, or be treated with other therapies.

BENEFITS
Targeted treatment with Cs-131 brachytherapy is able to limit dose to surrounding key structures: urethra, urinary sphincter, neurovascular bundles and healthy tissues. In addition, therapy requires no hospitalization, and a rapid return to prior activities.

IDEAL PATIENT
Candidates for targeted therapy will typically have low risk, localized disease, with low levels of PSA and Gleason scores, and low volume cancer as identified by MRI biopsy.

RISK STRATIFICATION
Tools to diagnose patient’s disease to determine if the patient can be treated with focal therapy: Fusion Biopsy, PSA, PSAD and tumor volume can be used together to predict uni-focal disease. Genomics can be used to exclude aggressive cancers.

isoray.com
For more information, please contact your Isoray sales representative or call Isoray at 509.375.5329.
WHAT IS TARGETED THERAPY?

Targeted therapy is the delivery of treatment to a portion of the prostate gland in order to deliver definitive therapy to identified disease while preserving surrounding tissue.

Different tissue-preserving strategies have been used across different series: (a) hockey stick, (b) hemiablation, (c) multifocal, and (d) unifocal strategies are shown in this representative scheme.1

WHY CESIUM-131 FOR TARGETED THERAPY?

Cesium-131 is an ideal isotope for targeted therapy. With a shorter half-life and higher energy than other commonly used radioisotopes, Cesium-131 by Isoray has been shown to be a highly effective cancer treatment with less side effects when planned appropriately and quicker recovery time.2

WHY ARE UROLOGISTS CONSIDERING TARGETED THERAPY?

• LIMIT PATIENT IMPACT

Patients considering targeted therapy are looking for a treatment like Cs-131 that has a limited impact on their Quality of Life (Potency/Continence) and allows for a quick return to activities.

• TREAT VS. WATCH

When diagnosed with low risk early stage prostate cancer, patients need to balance the need for treatment with the option for active surveillance. Cs-131 allows for patients to have an effective treatment and maintain their lifestyle.

• PRESERVES FUTURE OPTIONS

While a targeted treatment can be an effective treatment, in the event that additional prostate cancer develops, a treatment with Cs-131 will still allow for a variety of future additional treatment options.

“When focal [targeted] therapy is delivered with intention to treat, the perioperative, functional, and disease control outcomes are encouraging within a short to medium term follow-up. Focal therapy is a strategy by which the overtreatment burden of the current prostate cancer pathway could be reduced”1